Merck Presents Interim Phase 2a Trial Data on 1x Month Oral HIV Preventive

 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new interim data from the Phase 2a trial (NCT04003103) in adults evaluating the safety, tolerability and pharmacokinetics (PK) of the once-monthly oral islatravir tablet -- the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) -- for pre-exposure prophylaxis (PrEP). Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the two doses studied (60 mg and 120 mg). In the interim analysis using blinded data, both monthly doses of islatravir were found to have an acceptable tolerability profile. These data are shared as a late-breaking oral presentation during the virtual 2021 HIV Research for Prevention Conference (HIVR4P 2021) and featured in the official press conference of HIVR4P 2021.

https://www.businesswire.com/news/home/20210126005705/en/Merck-Presents-Interim-Findings-from-Phase-2a-Clinical-Trial-Evaluating-Investigational-Once-Monthly-Oral-Islatravir-for-the-Prevention-of-HIV-1-Infection-at-HIVR4P-2021